Programmed death ligand-2 (PD-L2), a PD-1 ligand, mediates cancer cell immune escape (or tolerance independent of PD-L1) and predicts poor prognosis of patients with HNSCC. This evidence concerns the gene PDCD1LG2 and head and neck squamous cell carcinoma.